Why is Artemis Medicare falling/rising?

Recent Price Movement and Market Performance

Artemis Medicare’s stock has been under pressure in the immediate term, with a consecutive seven-day losing streak resulting in a cumulative decline of 6.64%. The stock opened the day with a gap down of 2.43%, signalling early selling interest. Intraday, it touched a low of ₹265.30, marking a 3.07% drop from the previous close. This underperformance is notable when compared to the broader sector, as the stock lagged the sector by 1.73% on the day.

Over the past week, the stock has declined by 6.20%, significantly underperforming the Sensex, which fell only 0.53% in the same period. However, the one-month performance tells a different story, with Artemis Medicare gaining 9.54%, well ahead of the Sensex’s 2.16% rise. This suggests that while short-term sentiment has turned cautious, the medium-term trend remains positive.

Technical Indicators and Investor Participation

From a technical standpoint, the stock is trading above its 50-day, 100-day, and 200-day moving averages, indicating a generally positive long-term trend. However, it remains below its 5-day and 20-day moving averages, reflecting recent short-term weakness. This divergence often signals a temporary pullback within an overall uptrend.

Investor participation appears to be waning, with delivery volumes on 03 Dec falling by 16.03% compared to the five-day average. Reduced trading volumes can exacerbate price declines as fewer buyers are present to absorb selling pressure. Despite this, liquidity remains adequate, supporting trades of up to ₹0.1 crore without significant market impact.

Strong Fundamentals Underpinning the Stock

Despite the recent price softness, Artemis Medicare’s fundamentals remain robust. The company boasts a low Debt to EBITDA ratio of 1.34 times, underscoring its strong ability to service debt. Operating profit has grown at an impressive annual rate of 82.15%, reflecting healthy business expansion. Net profit growth of 41.51% was reported in the latest results for the quarter ending September 2025, marking the seventh consecutive quarter of positive earnings.

Operating cash flow for the year reached a high of ₹139.08 crore, while the return on capital employed (ROCE) stood at 13.34%, both indicators of efficient capital utilisation. The company’s debt-equity ratio remains low at 0.32 times, further reinforcing its conservative financial structure.

Valuation metrics also suggest the stock is attractively priced. With a return on equity (ROE) of 10.8 and a price-to-book value of 4.8, Artemis Medicare trades at a discount relative to its peers’ historical valuations. Although the stock has delivered a negative return of 20.66% over the past year, its profits have increased by 46.9%, resulting in a PEG ratio of 1.6, which indicates reasonable valuation relative to growth.

Balancing Short-Term Volatility with Long-Term Growth

The recent decline in Artemis Medicare’s share price can be attributed primarily to short-term selling pressure and reduced investor participation rather than any fundamental weakness. The stock’s underperformance relative to the Sensex and its sector over the past week highlights a phase of consolidation or profit-taking by market participants.

However, the company’s strong financial health, consistent profit growth, and attractive valuation metrics provide a solid foundation for future appreciation. Investors may view the current dip as a temporary correction within a broader uptrend, especially given the stock’s impressive three-year and five-year returns of 245.02% and 1283.82% respectively, far outpacing the Sensex.

In summary, while Artemis Medicare is experiencing a short-term price decline as of 04-Dec, its underlying business performance and financial strength suggest that the stock remains a compelling holding for investors with a medium to long-term horizon.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →